Oxford UK, 28 June 2011: PharmaVentures, experts in deals and alliances, are pleased to announce that they have recently been engaged by two major pharmaceutical companies to divest three facilities in three continents:
These new M&A mandates follow fast on the imminent closure of a sale of a European R&D facility and the successful divestment of three facilities for UCB and two for sanofi.
Fintan Walton, CEO of PharmaVentures, commented ” At PharmaVentures we are seeing an increasing number of top tier pharmaceutical companies looking to divest facilities as a result of consolidation or restructuring within their businesses. They trust PharmaVentures to provide the specialist skills and experience in valuing and positioning their assets for sale and then conducting a thorough proven process to deliver the best outcome. We are delighted that so many of the top Pharmaceutical companies recognise us as the provider of choice for these services.”
Kevin Bottomley, Head of Transactions stated ” Many of these facilities are very specialist and require expert knowledge to understand and convey the true value to potential acquirers. In selling these sites for continued or new uses we have been able to secure the future employment of thousands of people and facilitate new business growth.”
PharmaVentures is a leading life sciences transaction advisory firm with strong capabilities in finding and evaluating opportunities and negotiating deals. The transaction team has an established track record in generating outstanding value for PharmaVentures’ clients and has assisted in over 100 transactions in the past 20 years. Beyond that, PharmaVentures’ senior advisors have assisted over 500 leading companies in their growth needs including the areas of partnering and M&A.
– ends –